Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics

[1]  Guo Ci Teo,et al.  Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. , 2022, Cancer cell.

[2]  Ö. Ekinci,et al.  Succinate Dehydrogenase–Deficient Renal Cell Carcinoma , 2022, AJSP: Reviews and Reports.

[3]  G. Peters,et al.  Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  S. Piersma,et al.  Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors , 2021, HemaSphere.

[5]  H. Verheul,et al.  Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients , 2021, Clinical proteomics.

[6]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer , 2020, Cell.

[7]  Sen Li,et al.  Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma , 2020, Oncogene.

[8]  M. Selbach,et al.  mRNAs, proteins and the emerging principles of gene expression control , 2020, Nature Reviews Genetics.

[9]  C. Kang,et al.  PTRF/CAVIN1, regulated by SHC1 through the EGFR pathway, is found in urine exosomes as a potential biomarker of ccRCC. , 2020, Carcinogenesis.

[10]  Yi Hao,et al.  VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR , 2020, Oncogene.

[11]  Longzhen Zhang,et al.  Identification of the key genes and pathways involved in the tumorigenesis and prognosis of kidney renal clear cell carcinoma , 2020, Scientific Reports.

[12]  H. Verheul,et al.  Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines* , 2020, Molecular & Cellular Proteomics.

[13]  G. Peters,et al.  Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome , 2020, Cancers.

[14]  M. Savard,et al.  An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma. , 2020, European urology focus.

[15]  X. Mao,et al.  Emerging Roles of 5-Lipoxygenase Phosphorylation in Inflammation and Cell Death , 2019, Oxidative medicine and cellular longevity.

[16]  M. Životić,et al.  PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance , 2019, Diagnostic Pathology.

[17]  C. Porta,et al.  Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[18]  Guo Ci Teo,et al.  Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.

[19]  J. Yang,et al.  Myoferlin silencing inhibits VEGFR2-mediated proliferation of metastatic clear cell renal cell carcinoma , 2019, Scientific Reports.

[20]  G. G. Galli,et al.  PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma , 2019, Nature Communications.

[21]  H. Ahn,et al.  Dihydrotestosterone promotes kidney cancer cell proliferation by activating the STAT5 pathway via androgen and glucocorticoid receptors , 2019, Journal of Cancer Research and Clinical Oncology.

[22]  Yun Wang,et al.  Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer , 2019, Journal of Experimental & Clinical Cancer Research.

[23]  Andrea Bertotti,et al.  INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases , 2019, Molecular systems biology.

[24]  Qiu-ming He,et al.  Low expression of PDK1 inhibits renal cell carcinoma cell proliferation, migration, invasion and epithelial mesenchymal transition through inhibition of the PI3K-PDK1-Akt pathway. , 2019, Cellular signalling.

[25]  Alex A Henneman,et al.  INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases , 2019, Molecular systems biology.

[26]  A. Czarnecka,et al.  Insulin and insulin-like growth factors act as renal cell cancer intratumoral regulators , 2019, Journal of Cell Communication and Signaling.

[27]  E. Jonasch,et al.  Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). , 2019, The oncologist.

[28]  T. D. de Gruijl,et al.  Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial , 2019, Cancer Immunology, Immunotherapy.

[29]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[30]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[31]  Junhua Zheng,et al.  siRNA against TSG101 reduces proliferation and induces G0/G1 arrest in renal cell carcinoma – involvement of c-myc, cyclin E1, and CDK2 , 2019, Cellular & Molecular Biology Letters.

[32]  Jill P. Mesirov,et al.  A Curated Resource for Phosphosite-specific Signature Analysis* , 2018, Molecular & Cellular Proteomics.

[33]  L. O’Driscoll,et al.  Extracellular vesicles and anti-cancer drug resistance. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[34]  C. Ohyama,et al.  Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis , 2018, Medical Oncology.

[35]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[36]  R. Montironi,et al.  The Identification of Immunological Biomarkers in Kidney Cancers , 2018, Front. Oncol..

[37]  B. Kuster,et al.  The target landscape of clinical kinase drugs , 2017, Science.

[38]  K. Jeon,et al.  Prognostic role of myoferlin expression in patients with clear cell renal cell carcinoma , 2017, Oncotarget.

[39]  M. Spillman,et al.  A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells , 2017, Oncotarget.

[40]  G. Kristiansen,et al.  Systematic Expression Analysis of Mitochondrial Complex I Identifies NDUFS1 as a Biomarker in Clear‐Cell Renal‐Cell Carcinoma , 2017, Clinical genitourinary cancer.

[41]  Jun‐hang Luo,et al.  RIN1 promotes renal cell carcinoma malignancy by activating EGFR signaling through Rab25 , 2017, Cancer science.

[42]  G. Kristiansen,et al.  Systematic Analysis of the Expression of the Mitochondrial ATP Synthase (Complex V) Subunits in Clear Cell Renal Cell Carcinoma , 2017, Translational oncology.

[43]  H. Verheul,et al.  Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection. , 2017, Journal of proteomics.

[44]  P. Wee,et al.  Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways , 2017, Cancers.

[45]  N. Vogelzang,et al.  Axitinib Versus Sorafenib in First‐Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial , 2017, Clinical genitourinary cancer.

[46]  J. Li,et al.  Long noncoding RNA BX357664 regulates cell proliferation and epithelial-to-mesenchymal transition via inhibition of TGF-β1/p38/HSP27 signaling in renal cell carcinoma , 2016, Oncotarget.

[47]  C. Porta,et al.  Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach , 2016, Oncotarget.

[48]  F. Schena,et al.  The Three-Gene Signature in Urinary Extracellular Vesicles from Patients with Clear Cell Renal Cell Carcinoma , 2016, Journal of Cancer.

[49]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[50]  J. Barnard,et al.  MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model , 2016, British Journal of Cancer.

[51]  Ronald J. Moore,et al.  Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer , 2016, Cell.

[52]  C. Porta,et al.  Hormone signaling pathways as treatment targets in renal cell cancer (Review). , 2016, International journal of oncology.

[53]  Michael L. Gatza,et al.  Proteogenomics connects somatic mutations to signaling in breast cancer , 2016, Nature.

[54]  Chris Sander,et al.  Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. , 2016, Cell reports.

[55]  G. Smyth,et al.  ROBUST HYPERPARAMETER ESTIMATION PROTECTS AGAINST HYPERVARIABLE GENES AND IMPROVES POWER TO DETECT DIFFERENTIAL EXPRESSION. , 2016, The annals of applied statistics.

[56]  R. Montironi,et al.  Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma , 2015, Expert review of anticancer therapy.

[57]  C. Nelson,et al.  The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate Cancer , 2015, BioMed research international.

[58]  D. Jacqmin,et al.  Targeting FAK scaffold functions inhibits human renal cell carcinoma growth , 2015, International journal of cancer.

[59]  Wenquan Zhou,et al.  Expression of EphA2 protein is positively associated with age, tumor size and Fuhrman nuclear grade in clear cell renal cell carcinomas. , 2015, International Journal of Clinical and Experimental Pathology.

[60]  Y. Ishihama,et al.  Feasibility of label-free phosphoproteomics and application to base-line signaling of colorectal cancer cell lines. , 2015, Journal of proteomics.

[61]  H. Verheul,et al.  Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics. , 2015, Journal of proteomics.

[62]  B. Lei,et al.  Expression of PGAM1 in renal clear cell carcinoma and its clinical significance. , 2015, International journal of clinical and experimental pathology.

[63]  C. Porta,et al.  Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma , 2015, British Journal of Cancer.

[64]  Lei Zhang,et al.  BTG1 potentiates apoptosis and suppresses proliferation in renal cell carcinoma by interacting with PRMT1 , 2015, Oncology letters.

[65]  P. Cutillas.  Role of phosphoproteomics in the development of personalized cancer therapies , 2015, Proteomics. Clinical applications.

[66]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[67]  N. Rioux-Leclercq,et al.  Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting , 2015, Clinical Cancer Research.

[68]  Morag Park,et al.  Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes , 2014, Breast Cancer Research.

[69]  H. Verheul,et al.  Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms. , 2014, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[70]  A. Eggermont,et al.  eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies , 2014, Nature.

[71]  Michael D. Taylor,et al.  Genetic drivers of metastatic dissemination in sonic hedgehog medulloblastoma , 2014, Acta neuropathologica communications.

[72]  B. van Calster,et al.  Prognostic impact of baseline serum C‐reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib , 2014, BJU International.

[73]  N. Mongan,et al.  The role of HIF1α in renal cell carcinoma tumorigenesis , 2014, Journal of Molecular Medicine.

[74]  Junxia Zhang,et al.  High EphA2 protein expression in renal cell carcinoma is associated with a poor disease outcome , 2014, Oncology letters.

[75]  Wan-ning Hu,et al.  Interactions between filamin A and MMP-9 regulate proliferation and invasion in renal cell carcinoma. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[76]  Ronald J Moore,et al.  Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels* , 2014, Molecular & Cellular Proteomics.

[77]  E. Pasquale,et al.  Association of the Breast Cancer Antiestrogen Resistance Protein 1 (BCAR1) and BCAR3 Scaffolding Proteins in Cell Signaling and Antiestrogen Resistance* , 2014, The Journal of Biological Chemistry.

[78]  L. Campbell,et al.  Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease , 2013, Journal of Translational Medicine.

[79]  K. Miller,et al.  Expression parameters of the metabolic pathway genes pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC) , 2013, World Journal of Urology.

[80]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[81]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[82]  M. Mann,et al.  A large synthetic peptide and phosphopeptide reference library for mass spectrometry–based proteomics , 2013, Nature Biotechnology.

[83]  W. Kaelin,et al.  The VHL/HIF axis in clear cell renal carcinoma. , 2013, Seminars in cancer biology.

[84]  A. Stenzl,et al.  Evaluation of the KIT/stem cell factor axis in renal tumours. , 2012, Anticancer research.

[85]  S. Baba,et al.  C‐reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib , 2012, International journal of urology : official journal of the Japanese Urological Association.

[86]  J. Edwards,et al.  Expression and prognostic significance of Src family members in renal clear cell carcinoma , 2012, British Journal of Cancer.

[87]  Holger Moch,et al.  Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma , 2012, Cancer.

[88]  D. Berney,et al.  Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib , 2011, Oncogene.

[89]  Karl J. Dykema,et al.  Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas , 2011, Proceedings of the National Academy of Sciences.

[90]  A. Ullrich,et al.  Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells , 2010, Molecular oncology.

[91]  A. Ullrich,et al.  Overexpression of Csk-binding protein contributes to renal cell carcinogenesis , 2009, Oncogene.

[92]  L. Schwartz,et al.  NCCN clinical practice guidelines in oncology: kidney cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[93]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[94]  W. Linehan,et al.  Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. , 2008, European urology.

[95]  A. Pinto,et al.  Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes. , 2008, Molecular cell.

[96]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[97]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[98]  A. Bonfigli,et al.  Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. , 2007, Histology and Histopathology.

[99]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[100]  Katherine B Percarpio,et al.  Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. , 2006, Chemistry & biology.

[101]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[102]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[103]  Martin Kuiper,et al.  BiNGO: a Cytoscape plugin to assess overrepresentation of Gene Ontology categories in Biological Networks , 2005, Bioinform..

[104]  Y. Kawahito,et al.  5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. , 2005, Oncology reports.

[105]  M. Mann,et al.  Phosphotyrosine interactome of the ErbB-receptor kinase family , 2005, Molecular systems biology.

[106]  J. Rush,et al.  Immunoaffinity profiling of tyrosine phosphorylation in cancer cells , 2005, Nature Biotechnology.

[107]  N. Cordani,et al.  Expression of heat shock protein 27 in human renal cell carcinoma , 2004, Proteomics.

[108]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[109]  Xianglin Shi,et al.  Vanadate-induced Expression of Hypoxia-inducible Factor 1α and Vascular Endothelial Growth Factor through Phosphatidylinositol 3-Kinase/Akt Pathway and Reactive Oxygen Species* , 2002, The Journal of Biological Chemistry.

[110]  L. Schwartz,et al.  Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  R. Fisher,et al.  Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. , 2000, The cancer journal from Scientific American.

[112]  N. Sonenberg,et al.  Eukaryotic Translation Initiation Factor 4AIII (eIF4AIII) Is Functionally Distinct from eIF4AI and eIF4AII , 1999, Molecular and Cellular Biology.

[113]  A. Ravaud,et al.  Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .

[114]  M. Kawaichi,et al.  Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. , 1995, Cancer research.

[115]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[116]  Y. S. Green,et al.  Expression pattern of bcar3, a downstream target of Gata2, and its binding partner, bcar1, during Xenopus development. , 2016, Gene expression patterns : GEP.

[117]  B. Teh,et al.  Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. , 2008, Cancer research.

[118]  H. Izzedine,et al.  [Angiogenesis and renal cell carcinoma]. , 2007, Bulletin du Cancer.

[119]  D. Cooper,et al.  Integrin expression on cell adhesion function and up-regulation of P125FAK and paxillin in metastatic renal carcinoma cells. , 1996, Connective tissue research.